Trusted Resources: Education
Scientific literature and patient education texts
Inotersen for the Treatment of Adults With Polyneuropathy Caused by Hereditary Transthyretin-Mediated Amyloidosis
source: Expert Review of Clinical Pharmacology
year: 2019
authors: Gertz MA, Scheinberg M, Waddington-Cruz M, Heitner SB, Karam C, Drachman B, Khella S, Whelan C, Obici L
summary/abstract:Introduction:
Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is an underdiagnosed, progressive, and fatal multisystemic disease with a heterogenous clinical phenotype that is caused by TTRgene mutations that destabilize the TTR protein, resulting in its misfolding, aggregation, and deposition in tissues throughout the body.
Areas covered:
Inotersen, an antisense oligonucleotide inhibitor, was recently approved in the United States and Europe for the treatment of the polyneuropathy of ATTRv based on the positive results obtained in the pivotal phase 3 trial, NEURO-TTR. This review will discuss the mechanism of action of inotersen and its pharmacology, clinical efficacy, and safety and tolerability. A PubMed search using the terms ‘inotersen,’ ‘AG10,’ ‘antisense oligonucleotide,’ ‘hereditary transthyretin amyloidosis,’ ‘familial amyloid polyneuropathy,’ and ‘familial amyloid cardiomyopathy’ was performed, and the results were screened for the most relevant English language publications. The bibliographies of all retrieved articles were manually searched to identify additional studies of relevance.
Expert opinion:
Inotersen targets the disease-forming protein, TTR, and has been shown to improve quality of life and neuropathy progression in patients with stage 1 or 2 ATTRv with polyneuropathy. Inotersen is well tolerated, with a manageable safety profile through regular monitoring for the development of glomerulonephritis or thrombocytopenia.
DOI: 10.1080/17512433.2019.1635008read more full text
Related Content
-
The Coverage Battle Continues for Veterans With Transthyretin AmyloidosisThe Veterans Health Administration exist...
-
Nutrition Guidelines for Patients: Hereditary Transthyretin Amyloidosis (Spanish)Adopting simple, healthy habits is one o...
-
Screening for ATTR Amyloidosishttps://vimeo.com/580030784...
-
Neurological Complications of ATTR Amyloidosis by Dr. Chafic Karam – ASG Webinar 7.15.23 – 4/7https://www.youtube.com/watch?v=UcxmPgZ7...
-
Transthyretin Amyloidosis (ATTR): Rare Disease Prevalent in the Portuguese Communityhttps://www.oneamyloidosisvoice.com/wp-c...
-
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 st...CARLSBAD, Calif., April 24, 2023 /PRNe...
-
The Patient Journey Toward a Diagnosis of Hereditary Transthyretin (ATTRv) AmyloidosisBackground: Despite emerging treatments...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.